Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy

Abstract Tenofovir and entecavir are currently designated as the preferred oral antiviral drugs for chronic hepatitis B. However, only less than 40% of patients can achieve HBeAg seroconversion. We aim at investigating the role of intestinal microbiome in HBeAg seroconversion induced by oral antivir...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu-Li Zeng, Lei Qin, Wen-Jun Wei, Hong Cai, Xiao-Fang Yu, Wei Zhang, Xiao-Lu Wu, Xiao-Bin Liu, Wei-Ming Chen, Pan You, Mei-Zhu Hong, Yaming Liu, Xuan Dong, Ben-Chang Shia, Jian-Jun Niu, Jin-Shui Pan
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/796538f2eed8453fb934db7155a76d2a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:796538f2eed8453fb934db7155a76d2a
record_format	dspace
spelling	oai:doaj.org-article:796538f2eed8453fb934db7155a76d2a2021-12-02T10:44:08ZMeta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy10.1038/s41598-021-82939-12045-2322https://doaj.org/article/796538f2eed8453fb934db7155a76d2a2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-82939-1https://doaj.org/toc/2045-2322Abstract Tenofovir and entecavir are currently designated as the preferred oral antiviral drugs for chronic hepatitis B. However, only less than 40% of patients can achieve HBeAg seroconversion. We aim at investigating the role of intestinal microbiome in HBeAg seroconversion induced by oral antiviral therapy and describe multi-omics characteristics of HBeAg seroconversion associated intestinal flora. In this study, we prospectively collected fecal samples at baseline from the patients with HBeAg positive chronic hepatitis B who would have oral antiviral therapy. 16S rDNA sequencing and metabolomics were performed. We identified HBeAg seroconversion-related microbial signature and constructed prediction model for HBeAg seroconversion. Thirty-seven of these subjects achieved HBeAg seroconversion within 156 weeks after the initiation of oral antiviral therapy, while 41 subjects remained HBeAg positive even after over 156 weeks of therapy. A computational statistical and machine learning approach allowed us to identify a microbial signature for HBeAg seroconversion. Using random forest method, we further constructed a classifier based on the microbial signature, with area under curve being 0.749 for the test set. Patients who achieved HBeAg seroconversion tended to have lower abundance of certain fecal metabolites such as essential amino acids, and several dipeptides. By analyzing the fecal microbiota from the patients with and without HBeAg seroconversion, we showed intestinal microbiome play a critical role in HBeAg seroconversion induced by oral antiviral therapy. We also identified intestinal microbial signature that is associated with HBeAg seroconversion after oral antiviral therapy.Yu-Li ZengLei QinWen-Jun WeiHong CaiXiao-Fang YuWei ZhangXiao-Lu WuXiao-Bin LiuWei-Ming ChenPan YouMei-Zhu HongYaming LiuXuan DongBen-Chang ShiaJian-Jun NiuJin-Shui PanNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yu-Li Zeng Lei Qin Wen-Jun Wei Hong Cai Xiao-Fang Yu Wei Zhang Xiao-Lu Wu Xiao-Bin Liu Wei-Ming Chen Pan You Mei-Zhu Hong Yaming Liu Xuan Dong Ben-Chang Shia Jian-Jun Niu Jin-Shui Pan Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
description	Abstract Tenofovir and entecavir are currently designated as the preferred oral antiviral drugs for chronic hepatitis B. However, only less than 40% of patients can achieve HBeAg seroconversion. We aim at investigating the role of intestinal microbiome in HBeAg seroconversion induced by oral antiviral therapy and describe multi-omics characteristics of HBeAg seroconversion associated intestinal flora. In this study, we prospectively collected fecal samples at baseline from the patients with HBeAg positive chronic hepatitis B who would have oral antiviral therapy. 16S rDNA sequencing and metabolomics were performed. We identified HBeAg seroconversion-related microbial signature and constructed prediction model for HBeAg seroconversion. Thirty-seven of these subjects achieved HBeAg seroconversion within 156 weeks after the initiation of oral antiviral therapy, while 41 subjects remained HBeAg positive even after over 156 weeks of therapy. A computational statistical and machine learning approach allowed us to identify a microbial signature for HBeAg seroconversion. Using random forest method, we further constructed a classifier based on the microbial signature, with area under curve being 0.749 for the test set. Patients who achieved HBeAg seroconversion tended to have lower abundance of certain fecal metabolites such as essential amino acids, and several dipeptides. By analyzing the fecal microbiota from the patients with and without HBeAg seroconversion, we showed intestinal microbiome play a critical role in HBeAg seroconversion induced by oral antiviral therapy. We also identified intestinal microbial signature that is associated with HBeAg seroconversion after oral antiviral therapy.
format	article
author	Yu-Li Zeng Lei Qin Wen-Jun Wei Hong Cai Xiao-Fang Yu Wei Zhang Xiao-Lu Wu Xiao-Bin Liu Wei-Ming Chen Pan You Mei-Zhu Hong Yaming Liu Xuan Dong Ben-Chang Shia Jian-Jun Niu Jin-Shui Pan
author_facet	Yu-Li Zeng Lei Qin Wen-Jun Wei Hong Cai Xiao-Fang Yu Wei Zhang Xiao-Lu Wu Xiao-Bin Liu Wei-Ming Chen Pan You Mei-Zhu Hong Yaming Liu Xuan Dong Ben-Chang Shia Jian-Jun Niu Jin-Shui Pan
author_sort	Yu-Li Zeng
title	Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title_short	Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title_full	Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title_fullStr	Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title_full_unstemmed	Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title_sort	meta-omics characteristics of intestinal microbiota associated to hbeag seroconversion induced by oral antiviral therapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/796538f2eed8453fb934db7155a76d2a
work_keys_str_mv	AT yulizeng metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT leiqin metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT wenjunwei metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT hongcai metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT xiaofangyu metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT weizhang metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT xiaoluwu metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT xiaobinliu metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT weimingchen metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT panyou metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT meizhuhong metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT yamingliu metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT xuandong metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT benchangshia metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT jianjunniu metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy AT jinshuipan metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
_version_	1718396834259402752

Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy

Ejemplares similares